These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 18802169)

  • 1. From bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol.
    Colvin LA; Johnson PR; Mitchell R; Fleetwood-Walker SM; Fallon M
    J Clin Oncol; 2008 Sep; 26(27):4519-20. PubMed ID: 18802169
    [No Abstract]   [Full Text] [Related]  

  • 2. Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
    Richardson P
    Clin Adv Hematol Oncol; 2006 May; 4(5):4-5; discussion 8; suppl 13. PubMed ID: 16832859
    [No Abstract]   [Full Text] [Related]  

  • 3. Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report.
    Rodríguez-Martín M; Sáez-Rodríguez M; García-Bustínduy M; Martín-Herrera A; Noda-Cabrera A
    Dermatol Online J; 2008 Nov; 14(11):14. PubMed ID: 19094852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib-induced Sweet's syndrome.
    Van Regenmortel N; Van de Voorde K; De Raeve H; Rombouts S; Van de Velde A; Lambert J; Schroyens W
    Haematologica; 2005 Dec; 90(12 Suppl):ECR43. PubMed ID: 16464758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib-induced severe hepatitis in multiple myeloma: a case report.
    Rosiñol L; Montoto S; Cibeira MT; Bladé J
    Arch Intern Med; 2005 Feb; 165(4):464-5. PubMed ID: 15738379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Images in clinical Medicine. Bortezomib-induced skin lesions.
    Agterof MJ; Biesma DH
    N Engl J Med; 2005 Jun; 352(24):2534. PubMed ID: 15958809
    [No Abstract]   [Full Text] [Related]  

  • 7. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
    Richardson PG; Briemberg H; Jagannath S; Wen PY; Barlogie B; Berenson J; Singhal S; Siegel DS; Irwin D; Schuster M; Srkalovic G; Alexanian R; Rajkumar SV; Limentani S; Alsina M; Orlowski RZ; Najarian K; Esseltine D; Anderson KC; Amato AA
    J Clin Oncol; 2006 Jul; 24(19):3113-20. PubMed ID: 16754936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib in multiple myeloma.
    Meisler AI
    N Engl J Med; 2003 Sep; 349(13):1287-8; author reply 1287-8. PubMed ID: 14510013
    [No Abstract]   [Full Text] [Related]  

  • 9. Genetic variation associated with bortezomib-induced peripheral neuropathy.
    Favis R; Sun Y; van de Velde H; Broderick E; Levey L; Meyers M; Mulligan G; Harousseau JL; Richardson PG; Ricci DS
    Pharmacogenet Genomics; 2011 Mar; 21(3):121-9. PubMed ID: 21228734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma.
    Kenealy MK; Prince HM; Hönemann D
    Pharmacotherapy; 2006 Aug; 26(8):1205-6; discussion 1206. PubMed ID: 16863501
    [No Abstract]   [Full Text] [Related]  

  • 11. Bortezomib-induced skin eruption.
    Sanchez-Politta S; Favet L; Kerl K; Dietrich PY; Piguet V
    Dermatology; 2008; 216(2):156-8. PubMed ID: 18216478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unexpected cardiotoxicity in haematological bortezomib treated patients.
    Enrico O; Gabriele B; Nadia C; Sara G; Daniele V; Giulia C; Antonio S; Mario P
    Br J Haematol; 2007 Aug; 138(3):396-7. PubMed ID: 17561972
    [No Abstract]   [Full Text] [Related]  

  • 13. Bortezomib for myeloma -- much ado about something.
    Dispenzieri A
    N Engl J Med; 2005 Jun; 352(24):2546-8. PubMed ID: 15958811
    [No Abstract]   [Full Text] [Related]  

  • 14. [Severe bortezomib-induced peripheral neuropathy in a patient with multiple myeloma].
    Sanada Y; Nakazato T; Suzuki K; Mihara A; Aisa Y; Iwabuchi M; Kakimoto T
    Rinsho Ketsueki; 2010 Apr; 51(4):264-9. PubMed ID: 20467223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple myeloma.
    Crawford CL
    N Engl J Med; 2005 Feb; 352(8):840-1; author reply 840-1. PubMed ID: 15736295
    [No Abstract]   [Full Text] [Related]  

  • 16. Emergent T-helper 2 profile with high interleukin-6 levels correlates with the appearance of bortezomib-induced neuropathic pain.
    Mangiacavalli S; Corso A; De Amici M; Varettoni M; Alfonsi E; Lozza A; Lazzarino M
    Br J Haematol; 2010 Jun; 149(6):916-8. PubMed ID: 20201942
    [No Abstract]   [Full Text] [Related]  

  • 17. Severe pulmonary complications after bortezomib treatment in multiple myeloma.
    Dun X; Yuan Z; Fu W; Zhang C; Hou J
    Hematol Oncol; 2010 Mar; 28(1):49-52. PubMed ID: 19728395
    [No Abstract]   [Full Text] [Related]  

  • 18. Bortezomib-induced Sweet syndrome.
    Knoops L; Jacquemain A; Tennstedt D; Theate I; Ferrant A; Van den Neste E
    Br J Haematol; 2005 Oct; 131(2):142. PubMed ID: 16197442
    [No Abstract]   [Full Text] [Related]  

  • 19. Bortezomib (velcade) for multiple myeloma.
    Med Lett Drugs Ther; 2003 Jul; 45(1161):57-8. PubMed ID: 12865865
    [No Abstract]   [Full Text] [Related]  

  • 20. [Aggravated post-herpetic neuralgia due to bortezomib].
    Kirizume K; Imataki O; Shintani T; Fujihara S; Waki F; Ohue Y; Ohnishi H
    Rinsho Ketsueki; 2008 May; 49(5):331-4. PubMed ID: 18572810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.